Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that an abstract for its lead lung cancer candidate L‐DOS47 has been selected for oral presentation at the 16 World Conference on Lung Cancer (WCLC) held in Denver Colorado, September 6‐9,2015.
- 0 Comments
- FY2016